| Filed On | Filing |
|---|---|
| 11 Sep 2026 |
8-K: Completion of Acquisition or Disposition of Assets; Notice of Delisting or Failure to Satisfy a Listing Rule +4 more
Section 1. Annual Meetings. The annual meeting of the stockholders of AtaiBeckley Inc. (the “Corporation”) for the election of directors and for the transaction of such other business as may properly come before the meeting shall be held... |
| 08 Sep 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 8, 2026, AtaiBeckley Inc., a Delaware corporation (“AtaiBeckley”), held a virtual special meeting of its stockholders (the “Special Meeting”) to vote on the proposals identified in the definitive proxy statement of AtaiBeckl... |
| 31 Aug 2026 |
8-K: Other Events
As previously disclosed, AtaiBeckley Inc. (the “Company”) entered into an Agreement and Plan of Merger, dated as of July 15, 2026 (the “Merger Agreement”), with Eli Lilly and Company, an Indiana corporation (“Parent”) and Albali Acquisit... |
| 16 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure
This AGREEMENT AND PLAN OF MERGER, dated as of July 15, 2026 (this “Agreement”), is entered into by and among Eli Lilly and Company, an Indiana corporation (“Parent”), Albali Acquisition Corporation, a Delaware corporation and indirect w... |
| 08 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 4, 2026, AtaiBeckley Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). As of April 9, 2026, the record date for the Annual Meeting, there were approximately 366,916,896 shares of the Company’s c... |
| 03 Jun 2026 |
8-K: Regulation FD Disclosure
As previously announced, AtaiBeckley (the “Company”) will participate in multiple upcoming investor conferences in June 2026, as set forth below. Management will discuss program updates, including the initiation of the BPL-003 Phase 3 pi... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 |
| 09 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
AtaiBeckley Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of th... |
| 06 Mar 2026 |
8-K: Other Events
On June 2, 2025, atai Beckley N.V. (“atai”, f/k/a atai Life Sciences N.V.) entered into a share purchase agreement with Beckley Psytech Limited (“Beckley Psytech”) and certain selling shareholders of Beckley Psytech, pursuant to which at... |
| 06 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug Administration |
| 26 Feb 2026 |
8-K: Regulation FD Disclosure
February 26, 2026 EMP-01 (R-MDMA)Phase 2a Top Line Results in Social Anxiety Disorder (SAD) |
| 19 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”), is made and entered into as of the latest date next to the signatures below, by and between ATAI Life Sciences US, Inc. a Delaware corporation (the “Company”) and Michael Faerm (the... |
| 08 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
NEW YORK, UNITED STATES - 8 JANUARY 2026 – AtaiBeckley Inc (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing effective, rapid-acting and conve... |
Loading...